Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

First Berlin Equity Research has initiated coverage on Jaguar Health Inc., assigning a "Buy" rating with a target price of USD 60. The research, led by analyst Christian Orquera, highlights Jaguar's focus on plant-based pharmaceuticals for gastrointestinal health. Jaguar's flagship product, crofelemer (marketed as Mytesi®), is already FDA-approved for managing diarrhea in HIV/AIDS patients, generating annual sales of approximately USD 10-12 million.

Recent data on crofelemer from a Phase 3 trial indicated a significant improvement in diarrhea management for breast cancer therapy patients. This subgroup represented 62.7% of the trial's participants and could lead to US approval without additional trials. Jaguar is also developing treatments for severe rare diseases, with promising early data anticipated in 2025, potentially enhancing corporate partnerships and facilitating early approvals in Europe. With a strong pipeline addressing unmet needs, Jaguar is well-positioned for growth.